⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IMUX News
Immunic, Inc. Common Stock
Form 8-K
sec.gov
IMUX
Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer
prnewswire.com
IMUX
Form 8-K
sec.gov
IMUX
Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
prnewswire.com
IMUX
Form 8-K
sec.gov
IMUX
Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
prnewswire.com
IMUX
Immunic to Participate in Investor and Medical Conferences in May
prnewswire.com
IMUX
Form 8-K
sec.gov
IMUX
Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer
prnewswire.com
IMUX
Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsight
globenewswire.com
MRK
IPHA
VERU
KURA
INCY
AMGN
PFE
GILD
REGN
AZN
CRSP
BIIB
NTRA
ALLO
KYMR
ADCT
IMUX
CELC
ONON
ABBV
TDOC
BMY
IMVT
GNTX
IMPP
AUTL